De novo design of antiviral monobody binders
Monobodies (Mobs) are a class of immunoglobulin (Ig)-like proteins that have emerged as promising therapeutic scaffolds for applications ranging from antiviral therapy to cancer treatment. Unlike conventional monoclonal antibodies (mAbs), Mobs can be readily expressed in Escherichia coli at high yields, offering important advantages in overall developability. However, discovering antigen-specific Mobs with high binding affinity traditionally requires screening large, randomized in vitro libraries. To optimize Mob discovery, we developed MobGen, a computational pipeline for de novo design of Mob binders against viral antigens. As a proof of concept, we generated Mobs that bind the SARS-CoV-2 Spike glycoprotein Receptor Binding Domain (RBD). Subsequent in silico optimization improved production yield, thermal and conformational stability, binding affinity, and antiviral activity, demonstrating a promising approach for rapidly developing antibody-like molecules that target viral entry. These findings highlight MobGen's potential for de novo design of Mobs against emerging viruses with pandemic potential.
Authors
- José Valpuesta (ORCID: https://orcid.org/0000-0001-7468-8053)
- Javier Collado (ORCID: https://orcid.org/0000-0002-8707-6619)
- Miguel A. R. B. Castanho (ORCID: https://orcid.org/0000-0001-7891-7562)
- María Jesús Rodríguez-Espinosa (ORCID: https://orcid.org/0000-0003-1916-3195)
- Joseph H. Schmidt (ORCID: https://orcid.org/0009-0002-7512-1563)
- Ana Salomé Veiga (ORCID: https://orcid.org/0000-0002-9892-2243)
- Cláudio M. Soares (ORCID: https://orcid.org/0000-0003-1154-556X)
- Beatriz Vieira‐da‐Silva (ORCID: https://orcid.org/0000-0002-2242-2824)
- Marta Pires de Miranda (ORCID: https://orcid.org/0000-0003-3733-4963)
- Carlota J.F. Conceição (ORCID: https://orcid.org/0000-0001-5751-9960)
- Carolina C. Buga (ORCID: https://orcid.org/0000-0003-4109-8502)
- Christine Cruz-Oliveira (ORCID: https://orcid.org/0000-0003-4838-0703)
- João B. Vicente (ORCID: https://orcid.org/0000-0001-5244-8059)
- Maria João Amorim (ORCID: https://orcid.org/0000-0002-4129-6659)
- César A. Santiago (ORCID: https://orcid.org/0000-0002-5149-1722)
- Rocío Arranz (ORCID: https://orcid.org/0000-0001-5321-0915)
- Sandrine Georgeon (ORCID: https://orcid.org/0000-0002-8158-4508)
- Diana Lousa (ORCID: https://orcid.org/0000-0002-2309-0980)
- Marta Alenquer (ORCID: https://orcid.org/0000-0003-3062-1222)
- Pedro Moreira (ORCID: https://orcid.org/0000-0001-7734-1792)
- Isabel Alexandra Abreu (ORCID: https://orcid.org/0000-0002-5566-2146)
- Shuhao Xiao (ORCID: https://orcid.org/0000-0002-7522-3626)
- Haiyang Yu (ORCID: https://orcid.org/0000-0002-2419-6736)
- Diogo H.P. Silva (ORCID: https://orcid.org/0009-0005-0458-2997)
- Correia, Bruno, E
- Mariana Parada (ORCID: https://orcid.org/0000-0002-8179-5276)
- Jéssica Rodrigues (ORCID: https://orcid.org/0009-0001-5979-5982)
- Madalena C. Marques (ORCID: https://orcid.org/0009-0005-7923-9130)
Institutions
- City University of Hong Kong (HK)
- Universidade Católica Portuguesa (PT)
- Centro Nacional de Biotecnología (ES)
- Gulbenkian Institute for Molecular Medicine (PT)
- Instituto de Tecnologia Química e Biológica António Xavier (PT)
- Instituto Gulbenkian de Ciência (PT)
- École Polytechnique Fédérale de Lausanne (CH)
- Universidade Nova de Lisboa (PT)
Publication Details
- Journal
- bioRxiv (Cold Spring Harbor Laboratory)
- Published
- 2026-11-16
- DOI
- https://doi.org/10.64898/2026.11.12.760042
- Primary Topic
- Monoclonal and Polyclonal Antibodies Research
- Type
- preprint
Funders
- European Commission
- National Institutes of Health
- HORIZON EUROPE Framework Programme
- Fundação para a Ciência e a Tecnologia
- National Institute of Allergy and Infectious Diseases
- NextGenerationEU